A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

BACKGROUND: QL1604 is a humanized immunoglobulin G4 monoclonal antibody against programmed cell death protein 1. This first-in-human, open-label phase I study aimed to investigate the safety and tolerability and to identify the recommended doses of QL1604 for future studies. Pharmacokinetics/pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhiyu, Xu, Yanjun, Hong, Wei, Gong, Lei, Chen, Kaiyan, Qin, Jing, Xie, Fajun, Wang, Feng, Tian, Xin, Meng, Xiangrui, Feng, Wenlei, Li, Lingyan, Zhang, Baihui, Kang, Xiaoyan, Fan, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627225/
https://www.ncbi.nlm.nih.gov/pubmed/37936687
http://dx.doi.org/10.3389/fimmu.2023.1258573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627225/
https://www.ncbi.nlm.nih.gov/pubmed/37936687
http://dx.doi.org/10.3389/fimmu.2023.1258573

Ejemplares similares